Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety rollover study of luspatercept
NL-OMON60541Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of luspatercept in myelodysplastic syndrome (MDS), beta thalassemia and myelofibrosis (MF) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Adverse events, Progression to high/very high-risk myelodysplastic syndrome and 2 more. Started Jun 2020; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)beta thalassemiamyelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON60541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60541.